Table 1 Baseline characteristics of the patients

From: Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial

Characteristic

Patients (N = 46)

Age (years), median (range)

65 (52–76)

    <65, n (%)

19 (41.3)

    ≥65, n (%)

27 (58.7)

Gender, n (%)

    Male

45 (97.8)

    Female

1 (2.2)

Smoking status, n (%)

    Current/Former

37 (80.4)

    Never

9 (19.6)

ECOG PS, n (%)

    0

14 (30.4)

    1

32 (69.6)

Clinical stage, n (%)

    IIIB/IIIC

11 (23.9)

    IV

35 (76.1)

Pathologic subtypes, n (%)

    Squamous

43 (93.5)

    Mixed squamous NSCLC

3 (6.5)

PD-L1, n (%)

    TPS <1%

19 (41.3)

    TPS = 1–49%

11 (23.9)

    TPS ≥50%

3 (6.5)

    ND

13 (28.3)

  1. Source data are provided in the Source Data file.
  2. ECOG PS Eastern Cooperative Oncology Group Performance Status, ND not detectable, NSCLC non-small cell lung cancer, PD-L1 programmed cell death ligand-1, TPS tumor cell proportion score.
Back to article page